Rubius Therapeutics, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2022.

Location
Foxboro, MA
Fiscal year end
31 December
Latest financial report
27 Feb 2023

Quick Takeaways

  • Rubius Therapeutics, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2022.
  • Headline metric: Return On Equity -185%.

What Changed

  • Return On Equity YoY change: <span class="text-green-600">+51%</span>.
  • Most recent SEC facts end date: 31 Jan 2023.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2023-01-31) highlights Return On Equity -185.3%, Return On Assets -105.3%, and Current Ratio 2.54x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

33.1/100

Weak Confidence medium

Return On Equity

-185%

Metric score 0.0/100

Return On Assets

-105%

Metric score 0.0/100

Financial Health

Current Ratio
2.54x
Debt to Equity
1.45x

Strengths

Current Ratio

Watchpoints

Return On Equity, Return On Assets, and Debt-to-equity

Key metrics snapshot

Return On Equity

-185%

YoY: +51%

Industry median: -47% (n=218)

View history

Return On Assets

-105%

YoY: +60%

Industry median: -44% (n=217)

View history

Current Ratio

2.54x

YoY: -62%

Industry median: 3.67x (n=218)

View history

Debt-to-equity

1.45x

YoY: +161%

Industry median: 0.31x (n=169)

View history

NetIncomeLoss YoY

8.6%

YoY:

Industry median: -12% (n=211)

View history

Profitability

Metric Latest value YoY change
Return On Equity -185% +51%
Return On Assets -105% +60%

Financial Health

Metric Latest value YoY change
Current Ratio 2.54x -62%
Debt-to-equity 1.45x +161%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY 8.6%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 90,397,732 +0.35%
Common Stock, Shares, Outstanding 90,387,732 +0.36%
Common Stock, Value, Issued $90,000 0%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $96,414,000 -32%
General and Administrative Expense $30,835,000 -42%
Operating Income (Loss) $178,446,000 +8.3%
Nonoperating Income (Expense) $1,220,000 +37%
Cash and Cash Equivalents, at Carrying Value $14,865,000 -93%
Assets, Current $20,195,000 -91%
Property, Plant and Equipment, Net $146,000 -100%
Operating Lease, Right-of-Use Asset $2,679,000 -92%
Assets $23,070,000 -93%
Accounts Payable, Current $1,232,000 -89%
Employee-related Liabilities, Current $0 -100%
Liabilities, Current $7,939,000 -77%
Operating Lease, Liability, Noncurrent $0 -100%
Other Liabilities, Noncurrent $0 -100%
Liabilities $7,939,000 -94%
Retained Earnings (Accumulated Deficit) $856,684,000 -27%
Stockholders' Equity Attributable to Parent $15,131,000 -92%
Liabilities and Equity $23,070,000 -93%
Common Stock, Shares Authorized 300,000,000 +100%
Common Stock, Shares, Issued 90,387,732 +0.36%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14,915,000 -93%
Deferred Tax Assets, Valuation Allowance $263,429,000 +27%
Deferred Tax Assets, Gross $264,161,000 +21%
Operating Lease, Liability $1,100,000 -97%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $179,666,000 +8.6%
Lessee, Operating Lease, Liability, to be Paid $1,100,000 -98%
Property, Plant and Equipment, Gross $570,000 -99%
Operating Lease, Liability, Current $1,100,000 -88%
Lessee, Operating Lease, Liability, to be Paid, Year Two $0 -100%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,100,000 -88%
Operating Lease, Weighted Average Discount Rate, Percent 0 -105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 -100%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 -100%
Deferred Tax Assets, Operating Loss Carryforwards $159,691,000 +9.4%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 10,000,000 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 -100%
Additional Paid in Capital $871,725,000 +1.9%
Preferred Stock, Shares Outstanding 0
Share-based Payment Arrangement, Expense $15,783,000 -56%
Interest Expense $3,863,000 -40%
Preferred Stock, Par or Stated Value Per Share 0 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY